Invention Grant
- Patent Title: Heterocyclic compound
-
Application No.: US15474192Application Date: 2017-03-30
-
Publication No.: US10323026B2Publication Date: 2019-06-18
- Inventor: Shuhei Ikeda , Hideyuki Sugiyama , Jumpei Aida , Hidekazu Tokuhara , Tomohiro Okawa , Yuya Oguro , Minoru Nakamura , Masataka Murakami
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee Address: JP Osaka
- Agency: Foley & Lardner LLP
- Priority: JP2016-071181 20160331
- Main IPC: C07D413/14
- IPC: C07D413/14 ; C07D401/08 ; C07D405/14 ; C07D413/08 ; C07D401/06 ; C07D413/06

Abstract:
The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
Public/Granted literature
- US20170283406A1 HETEROCYCLIC COMPOUND Public/Granted day:2017-10-05
Information query